Cargando…

Synergic Renoprotective Effects of Combined ASC Therapy with RAAS Blockade in Experimental Advanced CKD

Global prevalence of chronic kidney disease (CKD) has increased considerably in the recent decades. Overactivity of the renin-angiotensin-aldosterone system (RAAS), associated to renal inflammation and fibrosis, contributes to its evolution. The treatments currently employed to control CKD progressi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maires, Marina P. C., Pereira, Krislley R., Silva, Everidiene K. V. B., Souza, Victor H. R., Teles, Flavio, Barbosa, Paulyana F., Garnica, Margoth R., Ornellas, Felipe M., Noronha, Irene L., Fanelli, Camilla
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8975629/ https://www.ncbi.nlm.nih.gov/pubmed/35371263 http://dx.doi.org/10.1155/2022/5111782

Ejemplares similares

Tamoxifen associated to the conservative CKD treatment promoted additional antifibrotic effects on experimental hypertensive nephrosclerosis
por: Fanelli, Camilla, et al.
Publicado: (2023)

Adipose-Derived Mesenchymal Stem Cells Modulate Fibrosis and Inflammation in the Peritoneal Fibrosis Model Developed in Uremic Rats
por: Costalonga, Elerson C., et al.
Publicado: (2020)

RAAS-Blockade in COVID-19: The Ace of Spades?
por: Agarwal, Krishna A., et al.
Publicado: (2021)

Mineralocorticoid receptor blockade for renoprotection
por: Cha, Dae Ryong
Publicado: (2018)

Mesenchymal Stromal Cells Induce Podocyte Protection in the Puromycin Injury Model
por: Ornellas, Felipe Mateus, et al.
Publicado: (2019)

Renoprotective RAAS inhibition does not affect the association between worse renal function and higher plasma aldosterone levels
por: Gant, Christina M., et al.
Publicado: (2017)

Renoprotection and the Bardoxolone Methyl Story – Is This the Right Way Forward? A Novel View of Renoprotection in CKD Trials: A New Classification Scheme for Renoprotective Agents
por: Onuigbo, Macaulay
Publicado: (2013)

Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial
por: Wachter, Rolf, et al.
Publicado: (2020)

Advances in understanding the renin-angiotensin-aldosterone system (RAAS) in blood pressure control and recent pivotal trials of RAAS blockade in heart failure and diabetic nephropathy
por: Ghazi, Lama, et al.
Publicado: (2017)

Single, Double and Triple Blockade of RAAS in Alport Syndrome: Different Tools to Freeze the Evolution of the Disease
por: Mastrangelo, Antonio, et al.
Publicado: (2021)

Acute kidney injury in a mouse model of meningococcal disease
por: Kolbe, Karin R, et al.
Publicado: (2021)

RAAS inhibition and mortality in hypertension
por: Ferrari, Roberto
Publicado: (2013)

The RAAS Goodfellas in Cardiovascular System
por: Caputo, Ilaria, et al.
Publicado: (2023)

Progenitor cell secretory products exert additive renoprotective effects when combined with ace inhibitors in experimental CKD
por: Kepecs, David M, et al.
Publicado: (2016)

RAAS INHIBITORS ARE CARDIOPROTECTIVE IN PATIENTS WITH COVID-19
por: Holmes, Adam R., et al.
Publicado: (2021)

Nutritional Treatment as a Synergic Intervention to Pharmacological Therapy in CKD Patients
por: Giannese, Domenico, et al.
Publicado: (2023)

Comparison of Severity of COVID-19 Infection among Patients Using RAAS Inhibitors and Non-RAAS Inhibitors
por: Reddy, Paidi Ramakrishna, et al.
Publicado: (2021)

Novel RAAS agonists and antagonists: clinical applications and controversies
por: Romero, Cesar A., et al.
Publicado: (2015)

System size scan of D meson RAA and vn using PbPb, XeXe, ArAr, and OO collisions
por: Noronha-Hostler, Jacquelyn
Publicado: (2020)

Antifibrotic Roles of RAAS Blockers: Update
por: Zhang, Ying-Ying, et al.
Publicado: (2019)

Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors
por: Duan, Xiaopin, et al.
Publicado: (2019)

The Role of Systolic Blood Pressure Reduction in Diastolic Dysfunction: RAAS Inhibition versus Non-RAAS Blood Pressure Lowering
por: Park, Sung-Ji
Publicado: (2020)

Effects of Direct Renin Blockade on Renal & Systemic Hemodynamics and on RAAS Activity, in Weight Excess and Hypertension: A Randomized Clinical Trial
por: Kwakernaak, A. J., et al.
Publicado: (2017)

RAAS: A Convergent Player in Ischemic Heart Failure and Cancer
por: Garcia-Garduño, Texali C., et al.
Publicado: (2021)

Heavy Ion RAA summary Plots 2022
por: The ATLAS collaboration
Publicado: (2022)

Development and Application of RAA Nucleic Acid Test Strip Assay and Double RAA Gel Electrophoresis Detection Methods for ASFV and CSFV
por: Wu, Keke, et al.
Publicado: (2022)

Renoprotective effects of garlic
por: Nasri, Hamid
Publicado: (2013)

Renoprotective effects of metformin
por: Nasri, Running Hamid
Publicado: (2013)

The renoprotective effects of sulodexide
por: Olde Engberink, Rik HG, et al.
Publicado: (2016)

The gray zone squamous lesions: ASC-US / ASC-H
por: Kattoor, Jayasree, et al.
Publicado: (2022)

CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection
por: Waitz, Rebecca, et al.
Publicado: (2012)

Renal Kallikrein Activation and Renoprotection after Dual Blockade of Renin-Angiotensin System in Diet-Induced Diabetic Nephropathy
por: Zou, Xia, et al.
Publicado: (2015)

Upregulation of Nrf2 and Decreased Redox Signaling Contribute to Renoprotective Effects of Chemerin Receptor Blockade in Diabetic Mice
por: Neves, Karla Bianca, et al.
Publicado: (2018)

The LIFT trial: study protocol for a double-blind, randomised, placebo-controlled trial of K(+)-binder Lokelma for maximisation of RAAS inhibition in CKD patients with heart failure
por: Murphy, Daniel, et al.
Publicado: (2021)

Heavy Ion Jet RAA Summary Plots 2023
por: The ATLAS collaboration
Publicado: (2023)

Update on RAAS Modulation for the Treatment of Diabetic Cardiovascular Disease
por: Bernardi, Stella, et al.
Publicado: (2016)

Renal Modulation: The Renin-Angiotensin-Aldosterone System (RAAS)
por: Natarajan, Aruna, et al.
Publicado: (2008)

RAAS inhibitors do not increase the risk of COVID-19
por: Fernández-Ruiz, Irene
Publicado: (2020)

COVID-19 and RAAS inhibitors: is there a final conclusion?
por: Talebi-Taher, Mahshid, et al.
Publicado: (2021)

RAAS inhibitors in COVID-19: not all are created equal!
por: Kow, Chia Siang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3qo6frlg7nr1fh3omosl61gpmk